Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director | May 01, 2023 | May 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date May 01, 2023 · Filed May 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-05-01 | Direct | 150,437 |
Reported balance
After 2023-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-01 · Grant · Acquired 150,437 · Balance 150,437 F1: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2023 Filed May 2, 2023 22:48 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 150,437 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-23-026731 · doc4.xml · derivative · entry 1 Ogier Walter C · CIK 0001344644 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,437 Underlying: Common Stock · 150,437 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 23:10 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006359 · doc4.xml · derivative · entry 1 Ogier Walter C · CIK 0001344644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:36 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-22-006485 · doc4.xml · derivative · entry 1 Ogier Walter C · CIK 0001344644 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.